Latest news with #Delhi-headquartered
News18
17-07-2025
- Business
- News18
Delhi, Mumbai going to be imp markets for DLF, says company official
Mumbai, Jul 17 (PTI) India's largest realty firm DLF Ltd, which has re-entered the Mumbai market with a premium housing project, on Thursday said it is taking its foray in the financial capital 'seriously" and the two geographies in the North and the West of India are going to be very important markets going forward. The Delhi-headquartered real estate giant also said that it has up to 20 joint venture proposals on its table from different entities, but it plans to establish its presence in the financial capital in a certain way. In July 2023, DLF announced its re-entry in the Mumbai market with plans to develop a luxury housing project in partnership with NCR-based builder Trident group. 'Mumbai (re-entry) we're taking very seriously. Both the cities – Mumbai and Delhi – are going to be two big markets (for us) because they're the ones who are going to give us our returns. So, if I have to invest in two geographies, I don't want to put all my eggs in one basket. 'These are the two very important markets going forward from here," DLF Home Developers Joint Managing Director Aakash Ohri told reporters at the unveiling of the project. The Rs 900-crore Westpark project, which is located just off Link Road in the western suburb of Andheri and is a part of a larger 10-acre Master Plan. It would have eight distinctive towers with the first four towers to be launched in the first phase, each having 37 storeys with a total of 416 residences, the company said. These towers would have a mix of three and four BHK residences, ranging from 1,125 sq ft to 2500 sq ft along with a limited number of exclusive penthouses. The groundbreaking for the project was carried out some three months back while the product (houses) will be launched in the first week of next month, DLF said. The company might sell the entire 416 units in case of high demand, Ohri said, adding, 'There is demand leading to something in Mumbai, and I think we need to partake in that whole demand scenario." The first phase itself has a revenue potential of Rs 2,300 crore with the next phase pegged at an estimated Rs 2,300-2,500 crore, he said, adding that 'about a year to a year-and-a-half, overall revenue potential is about Rs 5,000 crore." The company, he said, expects an overall revenue potential of Rs 10,000-crore across all phases at the current prices. He said that as it is difficult to get land parcels for such projects in a city like Mumbai, if there are joint venture development or other opportunities, the company will look at that in a very pragmatic way. 'We will look at opportunities in a very pragmatic way. I don't want to tick a box. We are not going to make any untoward statement or commitment to anybody, where we cannot or we are not serious about our delivery schedule. So we are starting with premium, and we will then move on to (other segments)." DLF has its offerings in three segments–superluxury, luxury and premium. 'We have right now 5-20 proposals sitting with us, of people wanting to do JV… But I want to start and get this product off the ground first," Ohri added. He said that the Mumbai project has evoked a good response from various segments in the form of expression of interest. Ohri also said that competition is always good as without competition one becomes an autocrat. 'Without competition, you will enter the monopolist markets. That is too dangerous. Competition will keep you and your systems on your toes. That is the best way to operate in any space," he said. 'You look at any product line– cars, mobile phones, airlines– wherever there is competition, you will be better. For me, I don't get perturbed by any competition," Ohri added. PTI IAS MR MR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
02-07-2025
- Business
- Economic Times
Rama Telecom set to list on NSE SME. Muted GMP ahead of debut
Delhi-headquartered Rama Telecom Limited is scheduled to list on the NSE SME platform on July 2, following the closure and allotment of its Rs 25.13 crore IPO. The GMP remains flat at Rs 0, indicating a subdued pre-listing sentiment and pointing to a potential listing around the issue price of Rs 68 per share. ADVERTISEMENT The IPO, which consisted entirely of a fresh issue of 36.96 lakh shares, saw investor participation between June 25 and 27, with allotments finalized on June 30. Despite a healthy business model focused on optical fibre cable (OFC) laying and telecom infrastructure, the absence of a premium in the unofficial market suggests cautious optimism from investors amid a busy SME listing week. Rama Telecom provides end-to-end network deployment services for major telecom players like Reliance Jio, Airtel, Vodafone Idea, BSNL, and others, with a strong portfolio in horizontal directional drilling, network design, commissioning, and data communication solutions. Its pan-India reach and client base in both public and private sectors offer a strategic moat in a capex-intensive the company has demonstrated robust growth, with FY25 revenue at Rs 42.47 crore, and a more-than-doubled PAT of Rs 5.53 crore, compared to Rs 2.61 crore in FY24. Margins have also improved, with EBITDA margins at 17.44% and PAT margins at 13.24%.While the company's fundamentals and order book offer long-term visibility, the IPO's price-to-earnings (P/E) ratio of 16.23x post-issue appears slightly full-valued for an SME counter, especially amid stiff competition and operational risks in large-scale infra execution. ADVERTISEMENT Post-issue, fresh capital earmarked for working capital needs, capex, and general corporate purposes. Investors and analysts will be closely watching if the stock can build momentum beyond listing and attract institutional interest in the secondary market. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
06-06-2025
- Automotive
- Time of India
JK Tyre targets 1 mn unit capacity expansion in FY26; bets on digitalisation for efficiency, ET Manufacturing
Automotive 2 min read JK Tyre targets 1 mn unit capacity expansion in FY26; bets on digitalisation for efficiency The Delhi-headquartered company will expand its tyre manufacturing capacity from 29 million units to about 30.5 million units in FY26, aided by the ₹1,400 crore capital expenditure (Capex) earmarked for the fiscal.
Time of India
06-06-2025
- Automotive
- Time of India
JK Tyre targets 1 mn unit capacity expansion in FY26; bets on digitalisation for efficiency
JK Tyre is looking to ramp up its manufacturing capacity in the current fiscal while also focusing on digitalisation of its operations to improve overall efficiency, said a top official of the company. 'We are basically increasing by another million. So, we are increasing capacity in passenger tyres, as well as in trucks and light trucks,' Anil Kumar Makkar, group chief sustainability officer, JK Organisation and manufacturing director, JK Tyre & Industries, told ETAuto. The Delhi-headquartered company will expand its tyre manufacturing capacity from 29 million units to about 30.5 million units in FY26, aided by the ₹1,400 crore capital expenditure (Capex) earmarked for the fiscal. The overall expansion will be driven by an increase in the capacity of its existing plants in Banmore, Madhya Pradesh, and Uttarakhand, Makkar said. The Banmore facility's capacity will be expanded from 20,000 to 30,000 tyres daily in the fiscal year 2026, with the balance being driven by the Uttarakhand plant. The company will majorly focus on increasing the production of radial tyres, a segment that currently serves the passenger car, truck, and light truck sectors. Digital Drive Across JK Tyre's Plants In order to achieve operational efficiency, the company is betting big on automation, enabled by artificial intelligence (AI) and machine learning (ML). The adoption has helped it reduce complaint resolution time from 20 days to just 20 minutes. At the Chennai plant, the tyre major has implemented digital traceability with barcode tracking from raw materials to finished goods. With data-backed decisions, Makkar said the company has been able to achieve a 'significant enhancement in efficiency'. 'We use data scientists to analyse data and identify gaps where we can improve. This has helped us increase the company's capacity by over 14 per cent,' he added. The company's Chennai and Banmore plants are almost fully equipped with the latest technologies, while the Uttarakhand plant is currently transforming. On the other hand, the Mexico plant is being modernised with the latest machinery to manufacture larger rim sizes of 18 inches to 21 inches. It currently serves the US market. With the incorporation of AI and digitalisation in the company's plants, the tyre major also aims to upskill its current workforce. Sustainability Initiatives The tyremaker has also set ambitious sustainability targets, including becoming carbon neutral by 2050. Currently, renewable energy accounts for 57 per cent of standalone operations, and approximately 45 per cent of the company's overall operations include the Cavendish acquisition. 'We are targeting around 70 per cent renewable power and also looking at roughly 60 to 65 per cent biomass usage…which will probably require some investment to upgrade boilers and related infrastructure. That is all fully planned,' the executive said.
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Fortis Healthcare rallies 9%, nears record high; brokerages see more upside
Fortis Healthcare share price today: Shares of Fortis Healthcare hit a four-month high of ₹731.35, as they rallied 9 per cent on the BSE in Thursday's intra-day trade amid heavy volumes on a healthy business outlook. The stock price of the hospital company is quoting at its highest level since January 8, 2025. It had hit a record high of ₹744 on December 30, 2024. At 11:13 AM, Fortis Healthcare stock was trading 8 per cent higher at ₹724.20 on the BSE. In comparison, the BSE Sensex was down 0.88 per cent at 80,880.47. The average trading volumes on the counter jumped over fourfold. A combined 5.72 million equity shares representing 0.76 per cent of the total equity of Fortis Healthcare have changed hands on the NSE and BSE. Fortis Healthcare Q4 & FY25 financial performance Delhi-headquartered hospital chain Fortis Healthcare on Tuesday, May 20, 2025, reported a 7.4 per cent year-on-year (Y-o-Y) fall in consolidated net profit for the March quarter of financial year 2024–25 (Q4FY25) at ₹188.02 crore, down from ₹203.14 crore in the same period last year. The decline in net profit was attributed to a 13.6 per cent Y-o-Y rise in total expenses, which stood at ₹1,741.52 crore, up from ₹1,531.76 crore. The company also cited impairments on investments in an associate firm and assets in a subsidiary, according to its regulatory filing. Revenue from operations rose to ₹2,007 crore in Q4FY25, marking a 12.4 per cent increase from ₹1,786 crore in Q4FY24. The increase in revenue was driven by strong performances in both the hospital and diagnostics businesses. Consolidated earnings before interest, tax, depreciation, and amortisation (Ebitda) rose 14.3 per cent Y-o-Y to ₹435 crore, with the Ebitda margin at 21.7 per cent, up from 21.3 per cent in the year-ago period. In FY25, the company's hospital business contributed 84 per cent to consolidated revenue compared to 82 per cent in FY24. Revenue from focus specialities comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopaedics and Renal Sciences grew 16 per cent Y-o-Y and contributed 62 per cent to overall hospital business revenues. The management said the company has witnessed a steady improvement in the diagnostics business Ebitda margins (excluding one-offs) at 22.0 per cent in FY25 compared to 19.6 per cent in FY24. The new brand is being well accepted and gaining prominence, placing the business in a better position to drive business expansion and enhance performance metrics, the management said. The company added 200 beds in FY25 and plans to add 993 beds in FY26, most of which are Brownfield projects. Brokerages' view on Fortis Healthcare JM Financial Institutional Securities - Due to ongoing efforts to improve the profitability of underperforming units, combined with significant Brownfield expansion, the company is poised to achieve over 15 per cent topline growth over the next three years, along with 200–300 bps margin expansion. With improved profitability, the company is also expected to generate ₹3,980 crore in free cash flow over the next three years. At the Wednesday market price of ₹672, the stock is trading at 26.2x on a 1Y forward EV/Ebitda basis, which the brokerage firm believes is likely to expand in the coming years due to improving fundamentals. 'We value the company on a SOTP basis to arrive at a target price (TP) of ₹810. Maintain BUY on the stock,' the brokerage firm said in the Q4 result update. Elara Capital - Strong growth continued in the hospitals segment. The management has guided for continued growth and a further 150- 200 bps margin expansion in FY26. Performance has started picking up in the diagnostics business as well – the management guided for double-digit growth in FY26, with margin recovering to ~23 per cent levels. 'We raise FY26E and FY27E core EPS estimates by 15-17 per cent, on strong guidance in both the business segments. So, we raise our TP to ₹749 from ₹686 – Retain Accumulate,' the brokerage firm said. About Fortis Healthcare Fortis Healthcare is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care speciality facilities. Currently, the company operates 27 healthcare facilities (including JVs and O&M facilities). The Company's network comprises approximately 4,750 operational beds (including O&M beds) and 404 diagnostics labs.
